GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (OTCPK:CYADY) » Definitions » Accounts Receivable

Celyad Oncology (Celyad Oncology) Accounts Receivable : $0.95 Mil (As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Celyad Oncology Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Celyad Oncology's accounts receivables for the quarter that ended in Jun. 2023 was $0.95 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Celyad Oncology's Net-Net Working Capital per share for the quarter that ended in Jun. 2023 was $-0.26.


Celyad Oncology Accounts Receivable Historical Data

The historical data trend for Celyad Oncology's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Accounts Receivable Chart

Celyad Oncology Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 0.17 0.20 0.23 0.96

Celyad Oncology Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 1.03 0.49 0.96 0.95

Celyad Oncology Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Celyad Oncology Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Celyad Oncology's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.952/0*91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Celyad Oncology's accounts receivable are only considered to be worth 75% of book value:

Celyad Oncology's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(5.391+0.75 * 0.952+0.5 * 0-12.09
-0-0)/22.594
=-0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Celyad Oncology Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Celyad Oncology (Celyad Oncology) Business Description

Traded in Other Exchanges
Address
Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.